352 related articles for article (PubMed ID: 34638613)
1. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.
Lee SK; Lee SW; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638613
[TBL] [Abstract][Full Text] [Related]
2. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
[TBL] [Abstract][Full Text] [Related]
3. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Urquijo-Ponce JJ; Alventosa-Mateu C; Latorre-Sánchez M; Castelló-Miralles I; Diago M
World J Gastroenterol; 2024 May; 30(19):2512-2522. PubMed ID: 38817666
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract][Full Text] [Related]
5. Immune-based therapies for hepatocellular carcinoma.
Pinato DJ; Guerra N; Fessas P; Murphy R; Mineo T; Mauri FA; Mukherjee SK; Thursz M; Wong CN; Sharma R; Rimassa L
Oncogene; 2020 Apr; 39(18):3620-3637. PubMed ID: 32157213
[TBL] [Abstract][Full Text] [Related]
6. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review.
Lin YJ; Ho CM
Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33540784
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Llovet JM; Pinyol R; Yarchoan M; Singal AG; Marron TU; Schwartz M; Pikarsky E; Kudo M; Finn RS
Nat Rev Clin Oncol; 2024 Apr; 21(4):294-311. PubMed ID: 38424197
[TBL] [Abstract][Full Text] [Related]
8. Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma.
Vanderborght B; De Muynck K; Gijbels E; Lefere S; Scott CL; Guilliams M; Beschin A; Vinken M; Verhelst X; Geerts A; Van Vlierberghe H; Devisscher L
Int J Cancer; 2023 Jun; 152(12):2615-2628. PubMed ID: 36912275
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.
Li L; Li ZZ; Pan LX; Su JY; Huang S; Ma L; Zhong JH
J Clin Transl Hepatol; 2024 May; 12(5):525-533. PubMed ID: 38779519
[TBL] [Abstract][Full Text] [Related]
10. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma.
Zeng Z; Yang B; Liao ZY
Oncol Lett; 2020 Oct; 20(4):45. PubMed ID: 32802167
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities.
Martin SP; Mehta N; Emamaullee J
Liver Transpl; 2024 Jul; 30(7):742-752. PubMed ID: 38345379
[TBL] [Abstract][Full Text] [Related]
12. Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software.
Ali E; Červenková L; Pálek R; Ambrozkiewicz F; Pavlov S; Ye W; Hošek P; Daum O; Liška V; Hemminki K; Trailin A
J Vis Exp; 2024 Apr; (206):. PubMed ID: 38682951
[TBL] [Abstract][Full Text] [Related]
13. IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma.
Aghayev T; Mazitova AM; Fang JR; Peshkova IO; Rausch M; Hung M; White KF; Masia R; Titerina EK; Fatkhullina AR; Cousineau I; Turcotte S; Zhigarev D; Marchenko A; Khoziainova S; Makhov P; Tan YF; Kossenkov AV; Wiest DL; Stagg J; Wang XW; Campbell KS; Dzutsev AK; Trinchieri G; Hill JA; Grivennikov SI; Koltsova EK
Cancer Discov; 2022 Aug; 12(8):1960-1983. PubMed ID: 35723626
[TBL] [Abstract][Full Text] [Related]
14. Retreatment with immunotherapy in a patient with hepatocellular carcinoma who received immune checkpoint inhibitors after primary curative treatment: a case report.
Wang T; Tang F; Li F; Yin W; Liang J
Front Oncol; 2024; 14():1321195. PubMed ID: 38646435
[TBL] [Abstract][Full Text] [Related]
15. Anti-stromal nanotherapeutics for hepatocellular carcinoma.
Yu Z; Huang L; Guo J
J Control Release; 2024 Mar; 367():500-514. PubMed ID: 38278367
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.
Zheng S; Chan SW; Liu F; Liu J; Chow PKH; Toh HC; Hong W
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672664
[TBL] [Abstract][Full Text] [Related]
17. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma.
Du JS; Hsu SH; Wang SN
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611100
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC.
Liu T; Guo Y; Liao Y; Liu J
Front Immunol; 2023; 14():1333864. PubMed ID: 38169837
[TBL] [Abstract][Full Text] [Related]
19. Photothermal Fibrous Chitosan/Polydopamine Sponge for Intraoperative Hemostasis and Prevention of Tumor Recurrence in Hepatocellular Carcinoma Resection.
Mu L; Qi L; Long H; Huang J; Zhong Z; Shi X; Chen C; Ye Q
Adv Sci (Weinh); 2024 Jan; 11(3):e2304053. PubMed ID: 38029340
[TBL] [Abstract][Full Text] [Related]
20. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.
Ganne-Carrié N; Nault JC; Ziol M; N'Kontchou G; Nahon P; Grando V; Bourcier V; Barge S; Beaugrand M; Trinchet JC; Seror O
Hepat Oncol; 2014 Oct; 1(4):395-408. PubMed ID: 30190975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
